Abbvie Inc.

J Martin Herold

Kristine E Frank

Michael M Friedman

Michael Z Hoemann

Noel S Wilson

Lu Wang

Augustine Osuma

Xiangdong Xu

Stacy A Van Epps

Raymond Huntley

Marlon D Cowart

Anil Vasudevan

Michael R Schrimpf

George S Sheppard

Huaqing Liu

Marc J Scanio

Maria A Argiriadi

Eric C Breinlinger

Kevin Patrick Cusack

Grier A Wallace

Heather M Davis

Dominique Bonafoux

Zhi Wang

Gagandeep K Somal

Matthew H Katcher

Jennifer Van Camp

Philip Cox

Thomas R Vargo

Matthew P Webster

Wei Qiu

David J Hardee

Ellen Yulin Tsai Chien

Andrew J Little

Disclosed herein are compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R, R2, R, R, R, X, X, X, X, X, nad n are as defined herein, pharmaeceutical compositions 2C X, and n are as defined herein, pharmaceutical compositions comprising same, and methods of preparation and use. 

Inhibitors of tyrosine kinase 2 mediated signaling

The invention provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions. 

Heterocyclic kinase inhibitors

The invention provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.

Primary carboxamides as BTK inhibitors

Growing community of inventors

Cambridge, MA, United States of America

J Martin Herold